{"organizations": [], "uuid": "036a0787c6ce2df2f949a80f4f4cfb77a7892375", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bellicum-pharmaceuticals-announces/brief-bellicum-pharmaceuticals-announces-clinical-hold-on-bpx-501-clinical-trials-in-u-s-idUSASB0C33W", "country": "US", "domain_rank": 408, "title": "BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T00:04:00.000+02:00", "replies_count": 0, "uuid": "036a0787c6ce2df2f949a80f4f4cfb77a7892375"}, "author": "", "url": "https://www.reuters.com/article/brief-bellicum-pharmaceuticals-announces/brief-bellicum-pharmaceuticals-announces-clinical-hold-on-bpx-501-clinical-trials-in-u-s-idUSASB0C33W", "ord_in_thread": 0, "title": "BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.", "locations": [], "entities": {"persons": [{"name": "bellicum", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "bellicum pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Bellicum Pharmaceuticals Inc:\n* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES\n* BELLICUM PHARMACEUTICALS INC - ‍RECEIVED NOTICE FROM U.S. FOOD AND DRUG ADMINISTRATION THAT U.S. STUDIES OF BPX-501 HAVE BEEN PLACED ON A CLINICAL HOLD​\n* BELLICUM PHARMACEUTICALS INC - ‍FDA CLINICAL HOLD DOES NOT AFFECT ONGOING BP-004 REGISTRATION TRIAL IN EUROPE​\n* BELLICUM PHARMACEUTICALS - STUDIES OF BPX-501 PLACED ON CLINICAL HOLD FOLLOWING THREE CASES OF ENCEPHALOPATHY DEEMED AS POSSIBLY RELATED TO BPX-501\n* BELLICUM PHARMACEUTICALS INC - BELLICUM IS AWAITING FORMAL COMMUNICATIONS FROM FDA TO DETERMINE REQUIREMENTS FOR RESUMING STUDIES Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-01-31T00:04:00.000+02:00", "crawled": "2018-01-31T00:22:53.002+02:00", "highlightTitle": ""}